Background Previous trials have demonstrated that lowering low-density lipoprotein (LDL)
cholesterol levels below currently recommended levels is beneficial in patients with acute …

Background Increased levels of the inflammatory biomarker high-sensitivity C-reactive
protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive …

Background Experimental and clinical data suggest that reducing inflammation without
affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory …

We performed a meta-analysis of 14 genome-wide association studies of coronary artery
disease (CAD) comprising 22,233 individuals with CAD (cases) and 64,762 controls of …

Background Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have
a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a …

ContextEvidence suggests that more intensive lowering of low-density lipoprotein cholesterol
(LDL-C) than is commonly applied clinically will provide further benefit in stable coronary …

Background High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor
of cardiovascular events. However, it is not clear whether this association is maintained at …

Background Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein
(LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse …

Background Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin
type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol …

Genes have a major role in the control of high-density lipoprotein (HDL) cholesterol (HDL-C)
levels. Here we have identified two Tangier disease (TD) families, confirmed 9q31 linkage …